TITLE

Sanofi-Aventis: near-term benign prostatic hyperplasia prospects look bleak

PUB. DATE
February 2010
SOURCE
PharmaWatch: Monthly Review;Feb2010, Vol. 9 Issue 2, p17
SOURCE TYPE
Market Research Report
DOC. TYPE
Opinion
ABSTRACT
In this article, the author discusses the Sanofi-Aventis SA's termination of its licensing agreement with AEterna Zentaris Inc. for the development of cetrorelix in benign prostatic hyperplasia (BPH) in the U.S. It mentions that the decision leaves the company with limited options to retain its near-term presence and revenue in the market. Datamonitor Ltd. stresses concern over the unfavorable side effects of cetrorelix such as the reduction of testosterone and possible menopausal symptoms.
ACCESSION #
47908535

 

Related Articles

  • BPH Market War Simmering; AEterna Slips, More to Come. Osborne, Randy // BioWorld Insight;8/24/2009, Vol. 17 Issue 34, p1 

    The article reports on the drug development study for cetrorelix for patient with prostate cancer. It cites Paul Blake, chief medical officer of AEterna Zentaris Inc., commenting on the result its Phase III of the development where it dit not get the expected positive result. Information on...

  • Sanofi-Aventis and AEterna Zentaris sign development agreement for BPH drug.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p15 

    The article reports on the signing of an agreement by Sanofi-Aventis US with AEterna Zentaris Inc. for the development of cetrorelix pamoate for benign prostatic hyperplasia treatment in the U.S. It is noted that cetrorelix pamoate, an intramuscular injection, is in three phase III trials in the...

  • UROGENITAL SYSTEM.  // Monthly Prescribing Reference;Jul2011, Vol. 27 Issue 7, p335 

    A chapter of the book "Monthly Prescribing Reference" is presented. It presents the drugs used for treating different types of urogenital disorders, including Amerifit Nutrition Inc.'s Urised for treating lower urinary tract discomfort due to hypermotility, Sanofi-Aventis SA's DDAVP for treating...

  • Cetrorelix Fails in BPH; Phase III Trial Continuing.  // Bioworld Week;8/24/2009, Vol. 17 Issue 34, p3 

    The article reports on the failure of the Phase III trial conducted by AEterna Zentaris Inc. in Quebec concerning the effectiveness of Cetrorelix in treating benign prostatic hyperplasia. Result of the study shows that placebo response are not higher than they saw in Phase II trials. However, a...

  • CLINIC ROUNDUP.  // BioWorld Today;6/11/2009, Vol. 20 Issue 111, p4 

    This section offers news briefs on the biotechnology industry. AEterna Zentaris Inc. has opened an extended study in the Phase III program with cetrorelix pamoate, a drug used for treating benign prostatic hyperplasia. The patient dosing in Altus Pharmaceuticals Inc.'s Phase II trial for...

  • Urinary Incontinence due to Overactive Detrusor Muscle: A Rare Side Effect of Venlafaxine. Selvaraj, Vithyalakshmi; Gunasekar, Palanikumar; Kumar, Suneel; Alsakaf, Imad // Case Reports in Urology;9/27/2015, Vol. 2015, p1 

    We report a case of reemergence of urinary incontinence (UI) in a patient with benign prostatic hyperplasia (BPH) after starting treatment with venlafaxine who was stabilized on tamsulosin and finasteride for about 6 years. A 66-year-old Caucasian male with prior history of major depressive...

  • dutasteride.  // Davis's Drug Guide for Nurses, 10th edition;2007, p440 

    The article presents a nursing guide to dutasteride, a benign prostatic hyperplasia agent. Indications and contraindications are mentioned. Adverse reactions to the drug are cited, including decreased libido and ejaculation disorders. Nursing implications and desired outcomes are provided. Drug...

  • WEEK IN REVIEW.  // BioWorld Insight;8/24/2009, Vol. 17 Issue 34, p5 

    The article offers updates related to financing in the pharmaceutical industries. Adamas Pharmaceuticals Inc. was able to raise 40 million dollars from its Series D financing and contracted with the U.S. Navy for its influenza A medicine. NeuroSearch A/S signed a 345 million dollars central...

  • Safety and Efficacy of BearxatXL Tablet (alfuzosin 10 mg) in Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Study of Primary Care Clinics. Seung-Ju Lee; Dong Sup Lee; Hyun-Sop Choe; Myung Sik Shin; Yong-Hyun Cho // Korean Journal of Andrology;Apr2012, Vol. 30 Issue 1, p71 

    Purpose: A prospective multi-center study was conducted to evaluate the safety and efficacy of alfuzosin (10 mg), for male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in primary care clinics. Materials and Methods: Three hundred twenty-four patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics